CYTK
Price
$40.43
Change
+$0.10 (+0.25%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
4.81B
6 days until earnings call
ERNA
Price
$0.22
Change
+$0.02 (+10.00%)
Updated
Apr 25, 04:59 PM (EDT)
Capitalization
12.74M
Ad is loading...

CYTK vs ERNA

Header iconCYTK vs ERNA Comparison
Open Charts CYTK vs ERNABanner chart's image
Cytokinetics
Price$40.43
Change+$0.10 (+0.25%)
Volume$14.36K
Capitalization4.81B
Ernexa Therapeutics
Price$0.22
Change+$0.02 (+10.00%)
Volume$1.14K
Capitalization12.74M
CYTK vs ERNA Comparison Chart
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. ERNA commentary
Apr 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a Buy and ERNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 26, 2025
Stock price -- (CYTK: $40.33 vs. ERNA: $0.20)
Brand notoriety: CYTK and ERNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 71% vs. ERNA: 83%
Market capitalization -- CYTK: $4.81B vs. ERNA: $12.74M
CYTK [@Biotechnology] is valued at $4.81B. ERNA’s [@Biotechnology] market capitalization is $12.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileERNA’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • ERNA’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than ERNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while ERNA’s TA Score has 5 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 4 bearish.
  • ERNA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ERNA is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а +2.15% price change this week, while ERNA (@Biotechnology) price change was +10.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.20%. For the same industry, the average monthly price growth was -4.19%, and the average quarterly price growth was -12.04%.

Reported Earning Dates

CYTK is expected to report earnings on Jul 31, 2025.

ERNA is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (+7.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.81B) has a higher market cap than ERNA($12.7M). CYTK YTD gains are higher at: -14.264 vs. ERNA (-30.306). ERNA has higher annual earnings (EBITDA): -36.12M vs. CYTK (-493.48M). CYTK has more cash in the bank: 1.08B vs. ERNA (1.73M). ERNA has less debt than CYTK: ERNA (684K) vs CYTK (789M). CYTK has higher revenues than ERNA: CYTK (18.5M) vs ERNA (582K).
CYTKERNACYTK / ERNA
Capitalization4.81B12.7M37,850%
EBITDA-493.48M-36.12M1,366%
Gain YTD-14.264-30.30647%
P/E RatioN/AN/A-
Revenue18.5M582K3,179%
Total Cash1.08B1.73M62,233%
Total Debt789M684K115,351%
FUNDAMENTALS RATINGS
CYTK vs ERNA: Fundamental Ratings
CYTK
ERNA
OUTLOOK RATING
1..100
174
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
66100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8597
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ERNA's Valuation (63) in the Medical Specialties industry is somewhat better than the same rating for CYTK (100) in the Biotechnology industry. This means that ERNA’s stock grew somewhat faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for ERNA (100) in the Medical Specialties industry. This means that CYTK’s stock grew somewhat faster than ERNA’s over the last 12 months.

CYTK's SMR Rating (99) in the Biotechnology industry is in the same range as ERNA (100) in the Medical Specialties industry. This means that CYTK’s stock grew similarly to ERNA’s over the last 12 months.

CYTK's Price Growth Rating (85) in the Biotechnology industry is in the same range as ERNA (97) in the Medical Specialties industry. This means that CYTK’s stock grew similarly to ERNA’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ERNA (100) in the Medical Specialties industry. This means that CYTK’s stock grew significantly faster than ERNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKERNA
RSI
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
STLD127.384.89
+3.99%
Steel Dynamics
ATS25.040.15
+0.60%
ATS Corp
COSM0.40N/A
+0.15%
Cosmos Health
NXRT36.62-0.20
-0.54%
NexPoint Residential Trust
HBIO0.39-0.01
-2.06%
Harvard Bioscience

ERNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with CGEN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERNA
1D Price
Change %
ERNA100%
+5.73%
CGEN - ERNA
39%
Loosely correlated
+2.78%
MDGL - ERNA
36%
Loosely correlated
+3.61%
IBIO - ERNA
32%
Poorly correlated
+11.80%
SMMT - ERNA
31%
Poorly correlated
+10.44%
CYTK - ERNA
29%
Poorly correlated
+6.13%
More